March 2007 Oncology News International

Publication
Article

Cover Story

Satraplatin Slows Progression of Refractory Prostate Ca

Focus on Breast Cancer

Brachytherapy Balloon Can Be Placed After Final Pathology

Focus on Hematology

Velcade Retreatment Safe, Effective for Relapsed Myeloma

Focus on Colon Cancer

Risks & Benefits of Adjuvant Chemotherapy for Colorectal Cancer: Are Your Patients Hearing What You're Saying?

Focus on Oncology Nursing

How to Prevent Inadvertent IT Administration of Vincristine

Recent Videos
According to Jorge Nieva, MD, there are a multitude of things that can be explored to enhance the treatment landscape for lung cancer.
5 experts are featured in this series
2 experts are featured in this series.
5 experts are featured in this series
2 experts are featured in this series.
Taletrectinib showed improved efficacy in patients with ROS1-positive non–small cell lung cancer who were treatment-naïve.
“It’s a drug that I’m very comfortable with, and it is a drug I’ll likely use primarily in the first-line setting,” stated Jorge Nieva, MD, on taletrectinib in non–small cell lung cancer.
4 experts in this video
4 experts in this video
Those being treated for peritoneal carcinomatosis may not have to experience the complication rates or prolonged recovery associated with surgical options.
Related Content